MedTrace Logo

Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer

NCT03426904 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 708

Last updated 2026-02-11

No results posted yet for this study

Summary

The main cause of recurrence after surgical treatment of colon cancer is distant metastasis. Neoadjuvant chemotherapy has potential benefits of improving the effectiveness of chemotherapy. Preoperative chemotherapy may eradicate microscopic metastatic cancer cells earlier than adjuvant chemotherapy, reduce cancer cell spillage during surgery, and lessen the invasiveness of surgical resection. This randomized multicenter phase III trial is assessing whether preoperative chemotherapy improves oncologic outcomes of patients with locally advanced colon cancer.

Conditions

Interventions

DRUG

Neoadjuvant FOLFOX

4 cycles of FOLFOX neoadjuvant chemotherapy and 8 cycles of postoperative chemotherapy

DRUG

Conventional adjuvant FOLFOX

12 cycles of postoperative FOLFOX chemotherapy

Sponsors & Collaborators

  • Kyungpook National University Hospital

    lead OTHER

Principal Investigators

  • Soo Yeun Park, MD · Kyungpook National University Chilgok Hospital

  • Gyu-Seog Choi, MD, PhD · Kyungpook National University Chilgok Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-23
Primary Completion
2028-12-28
Completion
2031-12-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03426904 on ClinicalTrials.gov